JPWO2020031936A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020031936A5 JPWO2020031936A5 JP2020535747A JP2020535747A JPWO2020031936A5 JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5 JP 2020535747 A JP2020535747 A JP 2020535747A JP 2020535747 A JP2020535747 A JP 2020535747A JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- amino acid
- drug conjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043043A JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018147582 | 2018-08-06 | ||
| JP2018147582 | 2018-08-06 | ||
| PCT/JP2019/030635 WO2020031936A1 (ja) | 2018-08-06 | 2019-08-05 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Division JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020031936A1 JPWO2020031936A1 (ja) | 2021-08-10 |
| JPWO2020031936A5 true JPWO2020031936A5 (https=) | 2022-08-15 |
| JP7458981B2 JP7458981B2 (ja) | 2024-04-01 |
Family
ID=69414755
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535747A Active JP7458981B2 (ja) | 2018-08-06 | 2019-08-05 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024043043A Pending JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Pending JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Pending JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Pending JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12497465B2 (https=) |
| EP (1) | EP3834843A4 (https=) |
| JP (3) | JP7458981B2 (https=) |
| KR (1) | KR20210042120A (https=) |
| CN (1) | CN112512587A (https=) |
| AU (2) | AU2019320336B2 (https=) |
| BR (1) | BR112021001750A2 (https=) |
| CA (1) | CA3108754A1 (https=) |
| EA (1) | EA202190471A1 (https=) |
| TW (1) | TW202019487A (https=) |
| WO (1) | WO2020031936A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3673918A4 (en) * | 2017-08-23 | 2021-05-19 | Daiichi Sankyo Company, Limited | PREPARATION OF AN ANTIBODY INGREDIENT CONJUGATE AND LYOPHILIZATION FOR IT |
| TW202019487A (zh) * | 2018-08-06 | 2020-06-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物及微管蛋白抑制劑之組合 |
| IL288485B2 (en) * | 2019-05-29 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-TROP2 antibody conjugates - a drug for use in cancer treatment |
| WO2021200131A1 (ja) * | 2020-03-30 | 2021-10-07 | 国立研究開発法人国立がん研究センター | 抗体薬物複合体 |
| KR20240038138A (ko) | 2020-07-13 | 2024-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
| IL301921A (en) * | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combining an antibody-drug conjugate and a selective 1PARP inhibitor |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药（苏州）股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| EP4265274B1 (en) * | 2020-12-18 | 2025-03-19 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| CN117881431A (zh) * | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
| WO2023042097A1 (en) * | 2021-09-15 | 2023-03-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| CN118955615B (zh) * | 2022-07-05 | 2026-01-30 | 上海药明合联生物技术有限公司 | 偶联连接子 |
| JPWO2024190815A1 (https=) * | 2023-03-14 | 2024-09-19 | ||
| TW202444427A (zh) * | 2023-03-31 | 2024-11-16 | 日商第一三共股份有限公司 | 抗CDH6抗體-藥物結合物與HIF-2α抑制劑之組合 |
| WO2025002310A1 (zh) * | 2023-06-29 | 2025-01-02 | 石药集团巨石生物制药有限公司 | 抗体-药物偶联物及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CA2486285C (en) | 2004-08-30 | 2017-03-07 | Viktor S. Goldmakher | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| AU2005322410B2 (en) | 2004-11-30 | 2011-11-10 | Amgen Fremont Inc. | Antibodies directed to GPNMB and uses thereof |
| NZ565075A (en) | 2005-06-20 | 2011-05-27 | Psma Dev Company Llc | PSMA antibody-drug conjugates |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| CA2862925C (en) | 2012-02-10 | 2020-01-21 | University Of Maryland, Baltimore | Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| CN103239455A (zh) * | 2012-12-24 | 2013-08-14 | 苏州大学 | 有协同治疗效果和高载药量的多组分纳米药物的制备方法 |
| LT3424955T (lt) | 2013-12-25 | 2025-06-25 | Daiichi Sankyo Company, Limited | Anti-trop2 antikūno ir vaisto konjugato gamybos būdas |
| SI3466976T1 (sl) * | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| JP6612738B2 (ja) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| KR102399277B1 (ko) | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| KR20170040249A (ko) * | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
| PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| EP4257134A3 (en) | 2015-06-25 | 2024-01-24 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
| WO2017100709A1 (en) * | 2015-12-09 | 2017-06-15 | Nant Holdings Ip, Llc | Compositions and methods for treatment of her2 positive metastatic breast cancer |
| EP3423105B1 (en) | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| BR112019011794A2 (pt) * | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| CA3050668C (en) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| ES3057444T3 (en) | 2017-08-31 | 2026-03-02 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
| TW202019487A (zh) * | 2018-08-06 | 2020-06-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物及微管蛋白抑制劑之組合 |
-
2019
- 2019-08-05 TW TW108127750A patent/TW202019487A/zh unknown
- 2019-08-05 KR KR1020217006189A patent/KR20210042120A/ko not_active Ceased
- 2019-08-05 BR BR112021001750-0A patent/BR112021001750A2/pt unknown
- 2019-08-05 CN CN201980052170.5A patent/CN112512587A/zh active Pending
- 2019-08-05 AU AU2019320336A patent/AU2019320336B2/en active Active
- 2019-08-05 EP EP19847036.1A patent/EP3834843A4/en active Pending
- 2019-08-05 EA EA202190471A patent/EA202190471A1/ru unknown
- 2019-08-05 JP JP2020535747A patent/JP7458981B2/ja active Active
- 2019-08-05 CA CA3108754A patent/CA3108754A1/en active Pending
- 2019-08-05 WO PCT/JP2019/030635 patent/WO2020031936A1/ja not_active Ceased
- 2019-08-05 US US17/266,465 patent/US12497465B2/en active Active
-
2024
- 2024-03-19 JP JP2024043043A patent/JP2024075668A/ja active Pending
- 2024-09-13 JP JP2024158824A patent/JP2024178243A/ja active Pending
-
2025
- 2025-09-04 AU AU2025226765A patent/AU2025226765A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020031936A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2025041725A5 (https=) | ||
| AU2019411289B2 (en) | Improved cell-targeting binding molecule | |
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP6328649B2 (ja) | 薬物−タンパク質コンジュゲート | |
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| JP6473138B2 (ja) | 癌、特に前立腺癌を標的とする合成抗体模倣化合物（ＳｙＡＭ） | |
| JP2008546792A5 (https=) | ||
| JP2020515578A5 (https=) | ||
| JP2013100314A5 (https=) | ||
| JP2017528418A5 (https=) | ||
| JP2020524675A5 (https=) | ||
| CA2967077A1 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JP2018537975A5 (https=) | ||
| JP2015500287A (ja) | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| JP2018509394A5 (https=) | ||
| JP2016511637A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| US20170281787A1 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
| JP2014508767A (ja) | 改善されたリンケージを有するアマトキシン複合体 | |
| JPWO2020027100A5 (https=) | ||
| JPWO2022102634A5 (https=) |